Lumos Diagnostics Holdings Limited
Q3 FY25 Investor Briefing

6 May 2025

Financial information is shown in USD unless otherwise stated.

www.lumosdiagnostics.com

Disclaimer and Important Information

This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company).

The information contained in this document ("Document") has been prepared by Lumos Diagnostics Holdings Limited (referred to as "Lumos" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Lumos periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein.

The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast. The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Lumos business and markets. Such information is generally based on independent market and industry data or research. Lumos has not independently verified and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Non-IFRS financial measures

Recipients should note that certain financial data included in this Document is not recognised under the AAS and is classified as 'non-IFRS financial information' under Regulatory Guide 230 'Disclosing non-IFRS financial information' published by ASIC. The Company believes that this non-IFRS financial information provides useful information to users in measuring the financial performance and condition of Lumos. The non-IFRS financial measures do not have standardised meanings under AAS, and therefore may not be comparable with similarly titled measures presented by other entities, nor should these be interpreted as an alternative to other financial measures determined in accordance with AAS. Investors are cautioned not to place undue reliance on any non-IFRS financial information, ratios and metrics included in this Document.

Company Overview

Who is Lumos and why do we exist?

Lumos develops, manufactures and distributes innovative diagnostic products
– delivering actionable information, in real time, at the point-of-care.

Improve the practice of medicine.

Unique Value Creation

Solving Unmet Medical Needs

- Developed and launched one of a kind proprietary point-of-care diagnostic product - FebriDx
- Transformational development agreements with the world's leading global women's health company – Hologic
- Currently developing women's health and sexual health point-of-care products for use at the point of care

Lumos Business Overview

Lumos offers end-to-end point of care (POC) diagnostic test development, from initial assay creation to high-volume manufacturing. We develop and sell our own tests and also create tests for customers under commercial contracts.



Proprietary and in-licensed POC diagnostic tests and systems for commercial sale

POC diagnostic tests, digital reader formats and digital applications developed for customers under commercial contracts

Able to leverage R&D, manufacturing scale, quality and regulatory skillset across Lumos' Products and Commercial Services divisions

Key Q3 FY25 Highlights

Key Highlights from Q3 FY25

Revenue of US$3.5 million for the quarter, up 21% compared to prior quarter (Q2 FY25 - US$2.9 million). YTD revenue of US$9.8 million, up 44% on PCP.

Product revenue was up 17% and Services revenue was up 22% on Q2 FY25.

Additional FebriDx® agreements completed in the U.S. 1) MedPro Associates and 2) U.S. Defense Logistics Agency (DLA) awarded FebriDx a Distribution and Pricing Agreement (DAPA) which authorizes sales representatives to promote to the US Military Services.

FebriDx - CLIA Waiver study continues with around 351 patients tested to-date and 37 bacterial positives. Study completion and FDA application anticipated in 2H CY2025.

Hologic fFN project scope of work expansion signed and expected to generate an additional US$0.6 - US$0.8 million in fee revenue.

Post Reporting Date: Medicare payor coverage adoption commences – FebriDx® added to Medicare Fee Schedule of four Medicare Administration Contractors (MACs) at $41.38 per test, effective April 2025. Discussions with the three remaining MACs progressing.

Financials Summary

(Quarterly, US$ in thousands)

Revenue ($'000)



Revenue Mix



Net Cash Generation ($'000)*



Commentary

- **Revenue** – US$3.5 million in Q3 FY25, up 21% on prior quarter. YTD revenue is US$9.8 million, up 44% on the PCP.
- **Services** revenue was US$2.8 million in Q3 FY25, up 22% on prior quarter, with a large contribution from development services under the Hologic fFN Development Agreement and the intellectual property licensing revenue associated with the IP Agreement.
- **Products** revenue was US$0.7 million in Q3 FY25, up 17% on prior quarter. Major contribution from ViraDx, plus increasing contribution from FebriDx in UK & US and small but growing Binx adoption.
- **Net cash outflow** of US$1.6 million in Q3 FY25, significant reduction on US$4.0 million outflow in Q2 FY25. Lower costs associated with inventory build up for US flu season, pre-clinical trial costs and other general operating costs.
- **Cash balance as at 31 March** of US$4.0 million.

**Net cash generation comprised of operating and investing cash flow, plus lease payments.*

Products Division

FebriDx® Update

Distribution agreements

Two new distribution agreements signed in the US with:

- MedPro Associates – across national hospital and primary care markets.
- U.S. Defense Logistics Agency (DLA) awarded FebriDx a Distribution and Pricing Agreement (DAPA) which authorizes sales representatives to promote to the US Military Services.

Medicare Benefits Schedule application

- In late March, Lumos completed and lodged an application with the Australian Government Department of Health and Aged Care for the inclusion of FebriDx® on the Medicare Benefits Schedule.

Extended supply agreement with Atomo Diagnostics

- During April, contract extended for Atomo's Pascal cassette, which is used in the FebriDx® test. The amended agreement extends the contract until 30 June 2031 and retains exclusivity for a CLIA waived product.

FebriDx® Update ...cont'd

Medicare US payor coverage adoption

- Effective from April 2025, FebriDx® has been added to the Medicare Fee Schedule in four of the seven Medicare Administration Contractors (MACs) regions - Palmetto, Novitas, First Coast Service Options and Noridian at US$41.38 per test.
- These four represent over 55% of the total US Medicare payment coverage.
- In discussions with the remaining three MACs.
- All seven MACs represent 20%-24% of the US payor mix

Map of US MAC Jurisdictions



FebriDx® CLIA Waiver Update

BARDA partnership agreement | October 2024

To support CLIA waiver and pediatric studies:
non-dilutive funding up to US$8.3m

- US$3.0m to support CLIA waiver study
- US$5.3m to support pediatric study (children under 12yrs old)
- Payments based on achieving certain milestones
- Next milestone payment is 500th patient, US$0.3 million

CLIA waiver clinical study commenced | December 2024

- Trial commenced on 19 December 2024 - first patient tested
- Around 351 patients tested to-date, with 37 bacterial positive (120 required)
- Bacterial prevalence lower than expected, at 10.5%
- Implementing patient enrollment “enrichment” plan
- Anticipate completion in 2H CY2025
- CLIA waiver enables access to a TAM of greater than US$1 billion in the US

ViraDx™

Point-of-Care test for key respiratory infections

ViraDx highly relevant POC test for post-pandemic environment

- SARS-CoV-2 pandemic increased consumer and healthcare point-of-care testing
- ViraDx is a 3-in-1 test for COVID-19/Flu A/Flu B

ViraDx market update

- ViraDx made up the majority of product sales during Q2 and Q3, with stocking orders received in October in preparation for the US flu season
- US flu season commenced some 6 – 8 weeks later than expected, now winding down
- ViraDx has achieved customer adoption due to the infection rates and great utility of the test - despite the US market experiencing significant competition from international organizations, with very aggressive pricing, at times below our COGS
- We are looking at alternative product distribution opportunities to sell a product that is competitive financially.

Lumos Future Products

Women's Sexual Health - $10B

Prevalence

Affects 30%-40% of women globally. >10M heath care visits annually in the US.



Clinical Need

Multiple infectious organisms. Similar symptoms / hard to diagnose. Different treatments for each. Patient samples currently sent to the core lab and can take days for results that potential mean delayed or incorrect diagnosis or treatment



POC Diagnostic Opportunity

Rapid & accurate testing close to the patient is needed. With a POC test(s), physicians can identify & treat at first patient visit. Easy to use & trusted by clinic staff.

Women's Sexual Health – The Opportunity

IN CLINIC TESTING

Physical Exam



Microscopic Exam

Pathogen Testing

EXTERNAL LAB TESTING

Pathogen Testing

Current Practice









Lumos Women's Sexual Health POC tests will be run by existing staff, cost effective and provide rapid and accurate results.

Reimbursement codes are available today.

Majority of clinics do not have in house testing of sexual health pathogens, due to test complexity, overheads and cost.

Instead, clinics send out testing to external labs, delaying patient diagnosis and treatment.

Lumos Product Roadmap | Women's Sexual Health

CURRENT - DISTRIBUTION
Revenue & Market Learning

FUTURE - LUMOS POC PRODUCTS
Pathogen Detection | Visual & Reader Interpretation

GYN CLINIC & URGENT CARE

Lumos – As a Distributer

Lumos Products – Visual Read

Lumos Products on Lumos Reader

Binx io
Chlamydia & Gonorrhea

Product #3

Product #4

Product #5

Product #1

Product #2

Concept Development

Technical Feasibility

Product Development

Verification & Validation

Commercialization

LUMOS DIAGNOSTICS

Commercial Services Division

Commercial Services Overview

Lumos works directly with clients to develop and deliver custom built, commercially viable point-of-care (POC) test solutions that meet business and end user needs.

Deep POC market insight

Broad POC immunoassay development expertise over a range of assay formats, specimen types, and sample matrices

Diverse proprietary digital reader platforms and cloud based technologies

Full in-house ISO 13485 compliant manufacturing including test strip manufacturing, assembly, kitting, and packaging

How we add value to partners

We work with partners through the whole diagnostic test product development cycle, then provide support once their products are in market.



Hologic - Strategic Partnership

Fetal Fibronectin (fFN)[1]

- fFN is a biomarker indicating a heightened risk of pre-term delivery and is the largest segment of the pre-term birth diagnostic test kit market of US$420m p.a.[2]
- Two agreements signed in FY24 for the development of an improved version of Hologic's leading in-market women's health product, Rapid fFN TLiQ, including adapting it for use on Lumos' proprietary reader platform
  - **IP Agreement** - US$10.0m - exclusive license to the Lumos proprietary reader and POC technologies for next generation fFN product – **received in FY24**
  - **Development Agreement** - up to US$5.5m over an estimated 24-month period for the following milestones:
    - **Phase 1:** Product Definition and Planning - US$0.4m - **completed**
    - **Phase 2:** Assay Feasibility - US$0.6m – milestone 1 **completed** / milestone 2 **in-progress (expect to complete in May)**
    - **Phase 3:** System Prototype Delivery – US$3.7m – 6 milestones – **commenced**
    - **Expanded HW scope of work** – announced Mar 2025 - US$0.6 – US$0.8m for delivery of new hardware features - **commenced**

[1]ASX announcements 11 January 2024, 15 January 2024, 16 January 2024, 6 May 2024, 4 June 2024, 19 June 2024. 3 March 2025 2. Global Market Insights, www.gminsights.com

Hologic - fFN Product development overview and opportunity

Current test: Rapid fFN TLiQ



Next generation test concept (mock-up)

Hologic – the opportunity ahead

- Verification and validation
- Clinical study
- Manufacturing
- Second test development and IP

Key Priorities

Key Priorities



Continue to monitor and implement strategies to maintain and improve the rate of bacterial positive patients enrolled in the FebriDx CLIA waiver trial

Incorporate FDA feedback from the FDA pre-submission for FebriDx pediatric study in April 2025 into an updated study protocol

Progress to formal product development on the first Lumos branded women's health diagnostics test

Continue to drive FebriDx product awareness and sales into US urgent care centers while expanding payor coverage with both US government and private insurance companies

Deliver on Hologic fFN development milestones - milestone 2 from Phase 2 & Phase 3 milestones

1. Detailed 1H FY25 financials available in Appendix

www.lumosdiagnostics.com